Interleukin 13

Manufactured by R&D Systems

Sourced in United States

Interleukin 13 is a cytokine that is involved in the regulation of immune and inflammatory responses. It is produced by a variety of cell types, including T cells, natural killer cells, and mast cells. Interleukin 13 plays a role in the differentiation of B cells, the inhibition of inflammatory cytokine production, and the promotion of tissue remodeling and fibrosis.

Automatically generated - may contain errors

Lab products found in correlation

Thp 1 cell, by American Type Culture Collection (2 mentions) Phorbol 12 myristate 13 acetate, by Merck Group (2 mentions) Interleukin 4 (il 4), by R&D Systems (2 mentions) Interleukin 4 (il 4), by Thermo Fisher Scientific (1 mentions) Lipopolysaccharide, by Merck Group (1 mentions) Recombinant human interleukin 2, by Thermo Fisher Scientific (1 mentions) Transwell chamber, by Corning (1 mentions) Etoposide, by Merck Group (1 mentions) Lipopolysaccharides (lps), by Merck Group (1 mentions) Dulbecco s mem, by Thermo Fisher Scientific (1 mentions) Mycoalert detection kit, by Lonza (1 mentions) Interferon γ, by R&D Systems (1 mentions)

Close spelling variants of this product

Interleukin 13 (IL-13) (2 citations)

3 protocols using interleukin 13

Macrophage Polarization from THP-1 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

THP-1 cells (American Type Culture Collection) were cultured at 37°C with 5% carbon dioxide in Roswell Park Memorial Institute 1640 medium (no. 2187509; Thermo Fisher Scientific) containing 10% fetal bovine serum. To differentiate monocytes into macrophages (M0), cells were incubated for 24 hours with 150 nmol/L phorbol 12-myristate 13-acetate (no. P8139PMA; Sigma/Merck), followed by 24 hours in Roswell Park Memorial Institute 1640 medium. M0 macrophages were consequently incubated with 20 ng/mL inteferon γ (no. PHC4031; Thermo Fisher Scientific) and 10 pg/mL lipopolysaccharide (no. 2630; Merck) for 24 hours, or with 20 ng/mL interleukin 4 (no. 200–04; Peprotech) and 20 ng/mL interleukin 13 (no. 213-ILB; R&D Systems) for 72 hours, for polarization into M1 or M2 macrophages, respectively.

Nilchian A., Plant E., Parniewska M.M., Santiago A., Rossignoli A., Skogsberg J., Hedin U., Matic L, & Fuxe J. (2020). Induction of the Coxsackievirus and Adenovirus Receptor in Macrophages During the Formation of Atherosclerotic Plaques. The Journal of Infectious Diseases, 222(12), 2041-2051.

+ Open protocol

+ Expand

Macrophage M2 Polarization in Tumor Co-Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

SNK6 and SNK6R cells were cultured in RPMI-1640 medium supplemented with heat-inactivated 10% fetal bovine serum (FBS), recombinant human interleukin-2 (PeproTech, Rocky Hill, NJ, USA), and treated with etoposide (Sigma-Aldrich, St Louis, MO, USA) to maintain drug resistance. For trans-well co-culture assays, THP-1 cells (ATCC, Rockville, MD, USA) were seeded into a 24-well plate (lower chamber, 3 × 10⁵) and differentiated into macrophages (M0) with 150 nM phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) for 24 h, after which the PMA-containing medium was replaced with 10% FBS containing a 1 × RPMI medium for 24 h. The SNK6R cells were then plated in a trans-well chamber (pore size, 0.4 μm; Corning Costar, Tewksbury, MA, USA) and incubated for 48 h. Cell densities were chosen to ensure a 1:1 ratio between SNK6R and THP-1 cells co-cultured in a 10% exosome-depleted FBS-cultured RPMI medium. Macrophage M2 polarization was obtained by incubation with 20 ng/mL of interleukin-4 (R&D Systems, Minneapolis, MN, USA) and 20 ng/mL of interleukin 13 (R&D Systems, USA) as previously reported [22 (link)].

Kim S.J., Ryu K.J., Park B., Yoon S.E., Cho J., Park Y, & Kim W.S. (2022). Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma. Cancers, 14(22), 5618.

+ Open protocol

+ Expand

Culturing and Differentiating Human Monocytic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

THP-1, ACHN, Caki-1, A498 and 786–0 cells were from ATCC (Manassas, VA), whereas RCC4, RCC10, UMRC2 and UOK101 were kind gifts from M. Celeste Simon (University of Pennsylvania). All commercially available cell lines were authenticated using STR fingerprinting upon receipt and stored in frozen aliquots. Fresh vials were thawed for use in experiments and discarded after 30–35 passages or approximately 2 months. Mycoplasma testing using the MycoAlert detection kit (Lonza, Ben OR) was performed every 2 months with the last test performed on February 2020. Cells were maintained at 37°C 5% CO₂ in Dulbecco’s MEM (Life Technologies, ThermoFisher Scientific, Waltham MA) or RPMI 1640 (THP-1 cells) with 10% FBS. Hypoxia incubations were performed using a Whitley H35 Hypoxystation (HypOxygen, Frederick, MO). THP-1 cells were activated to M0 by incubation with 50nM Phorbol 12-myristate 13-acetate (Sigma-Aldrich, St Louis, MO) for 24 hours. Differentiation from M0 to M1 cells was performed by treatment for 48 hours with 15ng/ml lipopolysaccharides (Sigma-Aldrich) and 50ng/ml interferon-γ (R&D Systems, Bio-Techne, Minneapolis, MN)). For M2 differentiation, cells were incubated with 5ng/ml interleukin-13 and 5ng/ml interleukin-4 (both from R&D Systems) for 48 hours.

Cowman S.J., Fuja D.G., Liu X.D., Tidwell R.S., Kandula N., Sirohi D., Agarwal A.M., Emerson L.L., Tripp S.R., Mohlman J.S., Stonhill M., Garcia G., Conley C.J., Olalde A.A., Sargis T., Ramirez-Torres A., Karam J.A., Wood C.G., Sircar K., Tamboli P., Boucher K., Maughan B., Spike B.T., Ho T.H., Agarwal N., Jonasch E, & Koh M.Y. (2020). Macrophage HIF-1α is an independent prognostic indicator in kidney cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(18), 4970-4982.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!